BCPT


Also found in: Acronyms.

BCPT

Breast Cancer Prevention Trial. A study of 13388 women at increased risk of breast cancer (BC): in women age 60+, < age 60 but at increased risk of BC, or with history of lobular carcinoma in situ, and randomised to receive tamoxifen or placebo.

Results
Tamoxifen reduces the risk of invasive BC by 49%; despite its side effects—e.g., increased risk of endometrial cancer, RR 2.53, stroke, pulmonary embolism and deep vein thrombosis—its use as a prophylaxis is appropriate in high-risk women.
References in periodicals archive ?
2] Nonstandard abbreviations: HPV, human papillomavirus; FAP, familial adenomatous polyposis; AK, actinic keratosis; PCPT, Prostate Cancer Prevention Trial; SELECT, Selenium and Vitamin E Cancer Prevention Trial; BCPT, Breast Cancer Prevention Trial; CARET, Beta-Carotene and Retinol Efficacy Trial; ATBC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention (trial); NSAID, nonsteroidal anti-inflammatory drug; FDA, US Food and Drug Administration; STAR, Study of Tamoxifen against Raloxifene; SERM, selective estrogen receptor-modulating agent; BCG, bacille Calmette-Guerin; DFMO, [alpha]-difluoromethylornithine (eflornithine).
In the BCPT, half the women took tamoxifen and half took a placebo (an inactive pill that looked like tamoxifen).
The BCPT revealed that for the first time, the incidence of breast cancer in women at high risk could be significantly reduced by taking tamoxifen.